Edition:
United States

Horizon Pharma PLC (HZNP.OQ)

HZNP.OQ on NASDAQ Stock Exchange Global Select Market

19.43USD
23 Sep 2016
Change (% chg)

$0.02 (+0.10%)
Prev Close
$19.41
Open
$19.32
Day's High
$19.83
Day's Low
$19.29
Volume
604,224
Avg. Vol
1,053,786
52-wk High
$25.56
52-wk Low
$12.86

HZNP.OQ

Chart for HZNP.OQ

About

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $3,126.38
Shares Outstanding(Mil.): 160.90
Dividend: --
Yield (%): --

Financials

  HZNP.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -0.02 -- --
ROI: -0.12 -0.26 13.91
ROE: -0.24 -3.05 14.82

BRIEF-Raptor Pharma says to pay Horizon Pharma termination fee of $30 mln if deal terminated

* In connection with termination of merger, Raptor will be required to pay to Horizon Pharma a termination fee of $30 million Source text for Eikon: [http://bit.ly/2celZU2] Further company coverage:

Sep 12 2016

BRIEF-Horizon pharma Q2 diluted earnings per share $0.09

* Horizon Pharma Plc announces second-quarter 2016 financial results

Aug 08 2016

Exclusive: Horizon Pharma explores potential stake sale - sources

Specialty pharmaceutical company Horizon Pharma Plc has hired Bank of America Corp to help it explore selling a significant equity stake to an investor that would bolster its balance sheet, people familiar with the matter said on Monday.

Jun 27 2016

Starboard seeks Depomed special shareholder meeting

Activist investor Starboard Value LP on Thursday formally called for a special meeting of Depomed Inc shareholders as it looks to replace the drugmaker' s board.

May 26 2016

UPDATE 2-Starboard seeks Depomed special shareholder meeting

May 26 Activist investor Starboard Value LP on Thursday formally called for a special meeting of Depomed Inc shareholders as it looks to replace the drugmaker' s board.

May 26 2016

BRIEF-Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim

* Says anticipates a reduction to 2016 adjusted ebitda of approximately $10 million versus prior guidance

May 19 2016

BRIEF-Horizon Pharma says settles patent litigation with Teligent

* Horizon Pharma Plc announces settlement of Pennsaid(r) (diclofenac sodium topical solution) 2 pct w/w patent litigation with Teligent Inc.

May 12 2016

BRIEF-Horizon Pharma says received notice of allowance from U.S. Patent Office

* Horizon Pharma announces u.s. Patent and trademark office issuance of additional notice of allowance with claims covering Krystexxa (pegloticase) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 11 2016

BRIEF-Horizon Pharma Plc says settled Pennsaid(R) patent litigation

* Horizon Pharma Plc announces settlement of Pennsaid(R) (diclofenac sodium topical solution) 2% w/w patent litigation with Amneal Pharmaceuticals Llc

Apr 25 2016

BRIEF-Depomed, Horizon Pharma Plc, Horizon Pharma Inc agree to settle claims

* On April 22, 2016, co,each of Horizon Pharma Plc and Horizon Pharma, Inc. mutually agreed to settle their respective claims against other

Apr 25 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.